US-based Frontage Laboratories Inc, a subsidiary of Frontage Holdings Corporation (HKEX:1521), has officially unveiled its newest Contract Research, Development and Manufacturing Organisation (CRDMO) facility during a grand open house event at its campus in Exton, Pennsylvania.

The event marked the official launch of 46,300-square-foot Good Manufacturing Practice (GMP) facility located at 240 Sierra Drive. This facility includes nine GMP suites: two high-potent suites, two aseptic suites and five non-sterile suites, supporting manufacturing for injectables, tablets, capsules, creams, gels, ointments, ophthalmic and nasal preparations. The building also houses two formulation development labs, and three analytical labs including a micro lab. It provides a comprehensive, one-stop-shop solution for pharmaceutical and biotech clients covering all aspects of clinical supplies, including formulation development, manufacturing, analytical testing, packaging, labelling, distribution and storage.

This expansion complements Frontage's existing service offerings, which include drug substance synthesis, DMPK, safety & toxicology studies, bioanalysis and clinical trial support.